Table 2 Availability of anti-malarials and malaria testing among anti-malarial stocking private sector outlets
From: The malaria testing and treatment landscape in mainland Tanzania, 2016
| Â | Private for-profit facility % CI | Pharmacy % CI | ADDO % CI | DLDB % CI | Private sector total % CI |
|---|---|---|---|---|---|
N=118 | N=60 | N=1468 | N=142 | N=1800 | |
QA ACT | 73.6 (63.0, 82.0) | 90.0 (75.0, 96.4) | 66.3 (57.7, 74.0) | 58.8 (42.8, 73.1) | 65.1 (57.2, 72.3) |
Non-QA ACT | 66.5 (49.0, 80.4) | 98.7 (94.2, 99.7) | 43.3 (33.1, 54.1) | 34.9 (21.3, 51.4) | 42.9 (31.5, 55.1) |
SP | 76.8 (70.0, 82.4) | 94.4 (90.2, 96.9) | 92.2 (87.9, 95.0) | 75.2 (62.2, 84.9) | 86.3 (80.4, 90.6) |
Oral quinine | 63.9 (49.0, 76.6) | 74.8 (61.7, 84.5) | 65.2 (57.7, 72.1) | 67.8 (51.5, 80.6) | 64.6 (57.9, 70.8) |
Other non-artemisinin therapy | 8.1 (3.9, 16.2) | 0.7 (0.1, 3.4) | 2.6 (1.3, 5.3) | 6.1 (2.6, 14.0) | 4.0 (2.3, 7.0) |
IV/IM artesunate | 34.4 (26.9, 42.9) | 17.9 (5.6, 44.5) | 0.2 (0.1, 0.8) | 0.0 (–) | 2.4 (1.4, 4.0) |
| Â | N=120 | N=61 | N=1490 | N=146 | N=1832 |
|---|---|---|---|---|---|
Any test | 96.0 (91.1, 98.3) | 21.9 (12.8, 34.8) | 10.2 (6.4, 15.9) | 8.1 (3.9, 16.2) | 15.7 (12.6, 19.4) |
Microscopy | 73.9 (51.0, 88.5) | 8.8 (1.8, 34.3) | 0.6 (0.2, 2.3) | 0.0 (–) | 5.4 (2.8, 10.3) |
RDT | 78.5 (69.4, 85.4) | 21.9 (12.8, 34.8) | 9.7 (6.0, 15.3) | 8.1 (3.9, 16.2) | 14.3 (11.4, 17.7) |